euro adhoc: Schering AG
other
Schering AG receives FDA approval for new low
dose oral contraceptive YAZ(R) with 24-day regimen
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement.
17.03.2006
Schering AG, Germany announced today that the U.S. Food and Drug Administration (FDA) has approved the new low dose, monophasic oral contraceptive YAZ(R) (3mg drospirenone/20 mcg ethinyl estradiol). It is the first pill with the innovative progestin drospirenone, and a low dose of ethinyl estradiol in a new dosing regimen of 24 days of active hormone pills and four days of placebo.
YAZ(R) will be launched in the U.S. in April 2006 by Berlex, Inc., a U.S. affiliate of Schering.
Schering continues to pursue FDA approval of YAZ(R) for the treatment of emotional and physical symptoms of premenstrual dysphoric disorder (PMDD), which is a severe form of premenstrual symptoms (PMS), among women who desire contraception.
end of announcement euro adhoc 17.03.2006 06:25:37
Further inquiry note:
Oliver Renner
Head Corporate Business Communication
Tel.: +49 (0)30 468 12431
Fax: +49 (0)30 468 16646
E-Mail: oliver.renner@schering.de
Branche: Pharmaceuticals
ISIN: DE0007172009
WKN: 717200
Index: DAX, CDAX, HDAX, Prime All Share
Börsen: Baden-Württembergische Wertpapierbörse / regulated dealing
Niedersächsische Börse zu Hannover / regulated dealing
New York / ADR
Frankfurter Wertpapierbörse / official dealing/prime standard
Börse Berlin-Bremen / official dealing
Hamburger Wertpapierbörse / official dealing
Börse Düsseldorf / official dealing
Bayerische Börse / official dealing